pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

8,127 products tracked · 88 matching

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health
viewlistcards
Phase 2
QA-102
Dry (Atrophic) Macular Degeneration
Guangzhou Yinming Biomedical Technology Co Ltd
1 catalysts
Phase 2
(difluprednate + povidone iodine)
(difluprednate + povidone iodine [USP])
Viral Conjunctivitis
iView Therapeutics Inc
0 catalysts
Phase 2
A-197
Keratoconjunctivitis Sicca (Dry Eye)
Aramis Biosciences Inc
0 catalysts
Phase 2
AAVB-039
← prev
page 1 of 3
next →
131
Pain89
Neurology1
Juvenile Macular Degeneration (Stargardt Disease)
AAVantgarde Bio Srl
0 catalysts
Phase 2
ABI-110
Polypoidal Choroidal Vasculopathy
Avirmax Inc
0 catalysts
Phase 2
ACDN-01
Juvenile Macular Degeneration (Stargardt Disease)
Ascidian Therapeutics Inc
0 catalysts
Phase 2
ANXV
Retinal Vein Occlusion
Annexin Pharmaceuticals AB
0 catalysts
Phase 2
ASP-7316
Juvenile Macular Degeneration (Stargardt Disease)
Astellas Pharma Inc
0 catalysts
Phase 2
ATSN-101
Leber Congenital Amaurosis (LCA)
Atsena Therapeutics Inc
0 catalysts
Phase 2
BRM-424
Neurotrophic Keratitis
BRIM Biotechnology Inc
0 catalysts
Phase 2
BS-01
Retinitis Pigmentosa (Retinitis)
Beacon Therapeutics Ltd
0 catalysts
Phase 2
CAM-101
Elate Ocular
Keratoconjunctivitis Sicca (Dry Eye)
Cambium Bio Limited
0 catalysts
Phase 2
CBT-004
Unspecified Ophthalmological Disorders
Cloudbreak Therapeutics LLC
0 catalysts
Phase 2
CBT-006
Keratoconjunctivitis Sicca (Dry Eye)
Cloudbreak Therapeutics LLC
0 catalysts
Phase 2
CSB-001
Neurotrophic Keratitis
Claris Biotherapeutics Inc
0 catalysts
Phase 2
CTx-001
Geographic Atrophy
B-cell lymphoma/leukemia 11A
Complement Therapeutics Ltd
0 catalysts
Phase 2
CTxPDE-6b
Retinitis Pigmentosa (Retinitis)
Coave Therapeutics
0 catalysts
Phase 2
DF-003
Chronic Kidney Disease (Chronic Renal Failure)
Drug Farm Inc
0 catalysts
Phase 2
DSP-3077
Retinitis Pigmentosa (Retinitis)
Sumitomo Pharma Co Ltd
0 catalysts
Phase 2
DT-168
Fuchs Endothelial Corneal Dystrophy (FECD)
Metabotropic glutamate receptor 4
$DSGNDesign Therapeutics, Inc.
0 catalysts
Phase 2
GLK-221
Keratoconus
$GKOSGLAUKOS Corp
0 catalysts
Phase 2
GLK-302
pilocarpine
Presbyopia
Muscarinic acetylcholine receptor M1Muscarinic acetylcholine receptor M3
$GKOSGLAUKOS Corp
0 catalysts
Phase 2
GLK-321
Demodex Blepharitis
$GKOSGLAUKOS Corp
0 catalysts
Phase 2
GLK-401
Age Related Macular Degeneration
$GKOSGLAUKOS Corp
0 catalysts
Phase 2
GRF-312
Keratoconjunctivitis Sicca (Dry Eye)
$GRFSGrifols SA
0 catalysts
Phase 2
GS-030
Retinitis Pigmentosa (Retinitis)
GenSight Biologics SA
0 catalysts
Phase 2
Gene Therapy to Activate Retinoschisin for X-Linked Retinoschisis
Retinal Degeneration
National Eye Institute
0 catalysts
Phase 2
H-1337
Open-Angle Glaucoma
D. Western Therapeutics Institute Inc
0 catalysts
Phase 2
IC-265
Allergic Conjunctivitis
IACTA Pharmaceuticals Inc
0 catalysts
Phase 2
IC-270
Allergic Conjunctivitis
IACTA Pharmaceuticals Inc
0 catalysts